Skip to main content

Table 1 Ranking of HTA Domains and assessment elements

From: Portable continuous wave Doppler ultrasound for primary healthcare in South Africa: can the EUnetHTA Core Model guide evaluation before technology adoption?

Element ID Topic/Issue Median (IQR) No of responses (%)
Health problem and current use of the technology (CUR) 5 (4,5) 24
  Target population   
A0007 What is the target population in this assessment? 5 (4,5) 24
A0023 How many people belong to this target population 5 (3.75, 5) 24
  Target condition   
A0002 What is the health condition 5 (4,5) 24
A0003 What are the known risk factors? 5 (4,5) 24
A0004 What is the natural course of the health condition? 4 (4,5) 23
A0005 What are the symptoms or health condition for the patient? 4 (4,5) 24
A0006 What are the consequences of the health condition for the society? 4.5 (4,5) 22
A0009 What aspects of the consequences are targeted by the Umbiflow? 4 (4,5) 23
  Current management of the condition   
A0018 What are the other typical or common alternatives to the Umbiflow? 4 (3.5,5) 23
A0024 How is the health condition currently diagnosed according to published guidelines and in practice? 4 (4,5) 24
A0025 How is the health condition currently managed according to published guidelines and in practice? 4 (4,5) 24
  Utilization   
A0001 For which health conditions and populations, and for what purposes is the technology used? 4 (3,5) 24
A0011 How much are the technologies utilized? 4 (3,5) 24
F0001 Is Umbiflow a new, innovative mode of care, an add-on to, or modification of a standard mode of care, or a replacement of a standard mode of care? 4 (3,5) 24
Description and technical characteristics of technology (TEC) 4 (3,5) 24
Safety (SAF) 5 (4,5) 24
  Patient safety   
C0006 What are the consequences of false positive, false negative and incidental findings generated by using the technology from the viewpoint of patient safety? 4 (3,5) 24
Clinical effectiveness (EFF) 4 (4,5) 23 (95.8)
  Mortality   
D0001 What is the expected beneficial effect of intervention on mortality? 4 (4,5) 24
  Morbidity  
D0005 How does using Umbiflow affect findings of the health condition? 4 (4,5) 24
D1004 What are the requirements for accuracy in the context where the technology will be used? 4 (3,5) 24
  Change-in-management  
D0020 Does use of the test lead to improved detection of the condition? 4 (4,5) 24
D0010 How does the technology modify the need for hospitalisation? 4 (3,5) 24
  Benefit-harm balance  
D0029 What are the overall benefits and harms of the technology in health outcomes? 4 (3,5) 24
Costs and Economic aspect 4 (3.4,5) 24
  Process-related costs   
G0006 What are the costs of processes related to acquisition and setting up new technology? 4 (3,5) 23
G0007 What are the likely budget impacts of implementing the technology? 4 (3,5) 23
Ethical aspect 4 (4,5) 24
  Autonomy   
F0006 Is there a need for any specific interventions or supportive actions concerning information in order to respect patient autonomy when the technology is used? 4 (3.5,5) 23
F0007 Does the implementation or withdrawal of the technology challenge or change professional values, ethics or traditional roles? 4 (3,4.5) 23
  Legislation   
F0014 Does the implementation or use of the technology affect the realisation of basic human rights? 4 (3,5) 23
Organizational aspect 4 (3,5) 24
  Health delivery process   
G0001 How does the technology affect the current work processes? 4 (3,5) 24
G0100 What kind of patient/participant flow is associated with the new technology? 4 (3,5) 24
G0002 What kind of involvement has to be mobilised for patients/participants and important others and/or caregivers? 4 (3,5) 21
G0003 What kind of process ensures proper education and training of staff? 4 (3,5) 23
  Management   
G0008 What management problems and opportunities are attached to the technology? 4 (3,5) 24
Patient and social aspect 4 (4,5) 23 (95.8)
  Patient’s perspectives   
H0100 What expectations and wishes do patients have with regard to the technology and what do they expect to gain from the technology? 4 (3,5) 24
  Communication aspects   
H0202 How are treatment choices explained to patients? 4 (3,5) 24
Legal aspect 4 (3.5,5) 23 (95.8)
  Autonomy of the patient   
I0034 Who is allowed to give consent for minors and incompetent persons? 4 (3,5) 24
  Privacy of the patient   
I0009 What do laws/binding rules require with regard to appropriate measures for securing patient data and how should this be addressed when implementing the technology? 4 (3.75,4.25) 24
\